# Clinical Trials Data EGFR - Document 122

# A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response

## Clinical Trial: https://clinicaltrials.gov/study/NCT01523340

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Informed consent\n\* 19\\~80 year old male or female\n\* Histologically proven advanced or metastatic NSCLC\n\* Failed to 1st line chemotherapy\n\* Tumor tissue for genetic analysis\n\* Evaluable target lesion by RECIST v1.1\n\* ECOG performance from 0 to 3\n\* Expected survival more than 12 weeks\n\nExclusion Criteria:\n\n\* Previous treatment of EGFR-tyrosine kinase inhibitors\n\* Severe hypersensitivity to erlotinib\n\* Residual toxicities (above grade 2) after previous chemotherapy\n\* Total bilirubin more than 1.5x of upper normal limit Liver function tests more than 2.5x of upper normal limits",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "19 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with histologically or cytologically confirmed stage IV or recurrent NSCLC who have progressive disease after 1st line chemotherapy who consent for study participation and meet the study selection criteria",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The information provided doesn't explicitly \*exclude\* patients with EGFR mutations. However, the exclusion criteria lists: "\* Previous treatment of EGFR-tyrosine kinase inhibitors".  
  
Therefore, a patient with an EGFR mutation \*could\* be eligible \*\*IF they have not previously been treated with an EGFR-tyrosine kinase inhibitor (TKI)\*\*. If they \*have\* received prior EGFR TKI treatment, they would be excluded.